Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Cross, N C P; White, H E; Colomer, D; Ehrencrona, H; Foroni, L; Gottardi, E; Lange, T; Lion, T; Machova Polakova, K; Dulucq, S; Martinelli, G; Oppliger Leibundgut, Elisabeth; Pallisgaard, N; Barbany, G; Sacha, T; Talmaci, R; Izzo, B; Saglio, G; Pane, F; Müller, M C; ... (2015). Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia, 29(5), pp. 999-1003. Nature Publishing Group 10.1038/leu.2015.29

Preview

Text EO_2014_leu201529a_Laboratory recommendations.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (261kB) | Preview

Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.Leukemia advance online publication, 27 February 2015; doi:10.1038/leu.2015.29.

Interest & Impact

Downloads

661 since deposited on 09 Apr 2015
18 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item